9 Papers
38 Citations
Jun Li is an academic researcher from Capital Medical University. The author has contributed to research in topics: Medicine & Gene. The author has an hindex of 3, co-authored 4 publications.
Chat about Author
Papers
MiR-503 suppresses cell proliferation and invasion of gastric cancer by targeting HMGA2 and inactivating WNT signaling pathway.
TL;DR: Results provide that miR-503 expression acts as a predictor for GC prognosis and may have a potential application in GC therapy.
HLA-DRB1*16:02 is associated with PEG-asparaginase hypersensitivity.
Shu-Guang Liu,Chao Gao,Ying Wu,Wei Lin,Jun Li,Tianlin Xue,Linya Wang,Huyong Zheng,Ruidong Zhang +8 more
TL;DR: In this paper, the associations between human leukocyte antigen (HLA)-DRB1 variants and the rs6021191 variant in nuclear factor of activated T cells 2 (NFATC2) with PEG-asparaginase hypersensitivity in children with acute lymphoblastic leukemia (ALL) treated according to the Chinese Children Leukemia Group (CCLG) ALL 2018 protocol were evaluated.
8
Central nervous system relapse in a pediatric anaplastic large cell lymphoma patient with CLTC/ALK translocation treated with alectinib: A case report.
Jing Yang,Jun Li,Wei-Yue Gu,Ling Jin,Yan-long Duan,Shuang Huang,Meng Zhang,Xisi Wang,Yi Liu,Chunju Zhou,Chao Gao,Huyong Zheng,Yonghong Zhang +12 more
TL;DR: An 8-year-old girl diagnosed with ALK+ALCL had extensive involvement and showed an extraordinary rare translocation, t(2;17)/CLTC-ALK, as demonstrated by RNA-seq, which showed significant and durable CNS effects in this patient.
7
Clinical, biological, and outcome features of P2RY8‐CRLF2 and CRLF2 over‐expression in pediatric B‐cell precursor acute lymphoblastic leukemia according to the CCLG‐ALL 2008 and 2018 protocol
TL;DR: In this article , the clinical, biological, and outcome features of pediatric BCP-ALL with CRLF2 abnormalities were explored, and the authors aimed to explore the clinical and biological features of the B-cell precursor acute lymphoblastic leukemia (BCP•ALL).
4
Prospective Evaluation of KIT Mutations and Long-Term Outcomes in Pediatric Core Binding Factor Acute Myeloid Leukemia: A Single Institutional Study in China.
B. Hou,Feifei Yang,Ruidong Zhang,M. Qin,Jun Li,Ying Wang,Hui Chen,Jing Li,Peijing Qi,Chenguang Jia,Huyong Zheng,C. Gao +11 more
TL;DR: This single-institution study in China evaluates the prognostic role of KIT mutations in pediatric core binding factor acute myeloid leukemia (CBF-AML), finding KIT mutations in 25.4% of patients, associated with poorer outcomes, particularly in RUNX1::RUNX1T1 subgroup.